Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Interstitial lung diseases
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …
Progressive pulmonary fibrosis: an expert group consensus statement
This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …
State-of-the-art evidence in the treatment of systemic sclerosis
JE Pope, CP Denton, SR Johnson… - Nature Reviews …, 2023 - nature.com
Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial
Background Systemic sclerosis is a connective tissue disease characterised by multiorgan
fibrosis with an autoimmune background and poor prognosis. Although a few drugs have …
fibrosis with an autoimmune background and poor prognosis. Although a few drugs have …
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities
Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …
Nintedanib for systemic sclerosis–associated interstitial lung disease
O Distler, KB Highland, M Gahlemann… - … England Journal of …, 2019 - Mass Medical Soc
Background Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …
and a leading cause of systemic sclerosis–related death. Nintedanib, a tyrosine kinase …
Systemic sclerosis-associated interstitial lung disease
A Perelas, RM Silver, AV Arrossi… - The Lancet respiratory …, 2020 - thelancet.com
Systemic sclerosis is an autoimmune connective tissue disease, which is characterised by
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …
immune dysregulation and progressive fibrosis that typically affects the skin, with variable …
Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
AM Hoffmann-Vold, Y Allanore, M Alves… - Annals of the rheumatic …, 2021 - Elsevier
Objectives To identify overall disease course, progression patterns and risk factors
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …
predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis …